{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jeremiah K"],"funding":["NIAID NIH HHS","Wellcome Trust"],"pagination":["3468-74"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4068463"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["58(6)"],"pubmed_abstract":["Nutritional supplementation to tuberculosis (TB) patients has been associated with increased weight and reduced mortality, but its effect on the pharmacokinetics of first-line anti-TB drugs is unknown. A cohort of 100 TB patients (58 men; median age, 35 [interquartile range {IQR}, 29 to 40] years, and median body mass index [BMI], 18.8 [17.3 to 19.9] kg/m(2)) were randomized to receive nutritional supplementation during the intensive phase of TB treatment. Rifampin plasma concentrations were determined after 1 week and 2 months of treatment. The effects of nutritional supplementation, HIV, time on treatment, body weight, and SLCO1B1 rs4149032 genotype were examined using a population pharmacokinetic model. The model adjusted for body size via allometric scaling, accounted for clearance aut"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV."],"pmcid":["PMC4068463"],"funding_grant_id":["UM1 AI106701","84323","UM1 AI068636"],"pubmed_authors":["Castel S","Changalucha J","Hagen CM","Range N","Wiesner L","Faurholt-Jepsen D","McIlleron H","Christiansen M","PrayGod G","Jeremiah K","Denti P","Chigutsa E","Friis H","Andersen AB"],"additional_accession":[]},"is_claimable":false,"name":"Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.","description":"Nutritional supplementation to tuberculosis (TB) patients has been associated with increased weight and reduced mortality, but its effect on the pharmacokinetics of first-line anti-TB drugs is unknown. A cohort of 100 TB patients (58 men; median age, 35 [interquartile range {IQR}, 29 to 40] years, and median body mass index [BMI], 18.8 [17.3 to 19.9] kg/m(2)) were randomized to receive nutritional supplementation during the intensive phase of TB treatment. Rifampin plasma concentrations were determined after 1 week and 2 months of treatment. The effects of nutritional supplementation, HIV, time on treatment, body weight, and SLCO1B1 rs4149032 genotype were examined using a population pharmacokinetic model. The model adjusted for body size via allometric scaling, accounted for clearance aut","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jun","modification":"2025-04-18T12:01:16.56Z","creation":"2019-03-27T01:30:45Z"},"accession":"S-EPMC4068463","cross_references":{"pubmed":["24709267"],"doi":["10.1128/aac.02307-13","10.1128/AAC.02307-13"]}}